Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Martina Seiffert, Sascha Dietrich, Alexander Jethwa, Hanno Glimm, Peter Lichter & Thorsten Zenz. (2012) Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia. Leukemia & Lymphoma 53:6, pages 1023-1031.
Read now
Read now
Elaine J. Schattner. (2002) Apoptosis in Lymphocytic Leukemias and Lymphomas. Cancer Investigation 20:5-6, pages 737-748.
Read now
Read now
Naruo Kuwashima, Shigeru Kageyama, Yoshikatsu Eto & Mitsuyoshi Urashima. (2001) CD40 Ligand Immunotherapy in Cancer: An Efficient Approach. Leukemia & Lymphoma 42:6, pages 1367-1377.
Read now
Read now
Articles from other publishers (39)
Alice O’Donnell, Chris Pepper, Simon Mitchell & Andrea Pepper. (2023) NF-kB and the CLL microenvironment. Frontiers in Oncology 13.
Crossref
Crossref
Mirco Di Marco, Serena Veschi, Paola Lanuti, Alice Ramassone, Stefania Pacillo, Sara Pagotto, Felice Pepe, Jonahunnatha Nesson George-William, Claudia Curcio, Marco Marchisio, Sebastiano Miscia, Idanna Innocenti, Francesco Autore, Barbara Vannata, Patrizia Di Gregorio, Mario Di Gioacchino, Silvia Valentinuzzi, Manuela Iezzi, Renato Mariani-Costantini, Luigi Maria Larocca, Luca Laurenti, Angelo Veronese & Rosa Visone. (2021) Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response. Cancers 13:2, pages 257.
Crossref
Crossref
Vanessa Innao, Vincenzo Rizzo, Andrea Gaetano Allegra, Caterina Musolino & Alessandro Allegra. (2020) Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs. Current Oncology 28:1, pages 159-183.
Crossref
Crossref
Yoichi Tatsumi. 2018. Resistance to Ibritumomab in Lymphoma. Resistance to Ibritumomab in Lymphoma
9
31
.
Elinor A. Chapman, Melanie Oates, Ishaque S. Mohammad, Barry R. Davies, Paul K. Stockman, Jianguo Zhuang & Andrew R. Pettitt. (2017) Delineating the distinct role of AKT in mediating cell survival and proliferation induced by CD154 and IL-4/IL-21 in chronic lymphocytic leukemia. Oncotarget 8:61, pages 102948-102964.
Crossref
Crossref
Weiguo Han, David A. Jackson, Stephan J. Matissek, Jason A. Misurelli, Matthew S. Neil, Brandon Sklavanitis, Nansalmaa Amarsaikhan & Sherine F. Elsawa. (2017) Novel Molecular Mechanism of Regulation of CD40 Ligand by the Transcription Factor GLI2. The Journal of Immunology 198:11, pages 4481-4489.
Crossref
Crossref
Francesca Arruga & Silvia Deaglio. 2018. Mechanisms of Drug Resistance in Cancer Therapy. Mechanisms of Drug Resistance in Cancer Therapy
203
229
.
Larry Mansouri, Nikos Papakonstantinou, Stavroula Ntoufa, Kostas Stamatopoulos & Richard Rosenquist. (2016) NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions. Seminars in Cancer Biology 39, pages 40-48.
Crossref
Crossref
Paula Cramer, Barbara Eichhorst, Hans Christian Reinhardt & Michael Hallek. (2016) Current strategies to create tailored and risk-adapted therapies for CLL patients. Best Practice & Research Clinical Haematology 29:1, pages 111-121.
Crossref
Crossref
Lukas P. Frenzel, H. Christian Reinhardt & Christian P. Pallasch. (2016) Concepts of Chronic Lymphocytic Leukemia Pathogenesis: DNA Damage Response and Tumor Microenvironment. Oncology Research and Treatment 39:1-2, pages 9-16.
Crossref
Crossref
Lesley-Ann Sutton & Richard Rosenquist. (2015) The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia. Seminars in Cancer Biology 34, pages 22-35.
Crossref
Crossref
Rebekah L. Browning, Xiaokui Mo, Natarajan Muthusamy & John C. Byrd. (2015) CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathway. Oncotarget 6:18, pages 15931-15939.
Crossref
Crossref
Angela Garding, Nupur Bhattacharya, Rainer Claus, Melanie Ruppel, Cordula Tschuch, Katharina Filarsky, Irina Idler, Manuela Zucknick, Maïwen Caudron-Herger, Christopher Oakes, Verena Fleig, Ioanna Keklikoglou, Danilo Allegra, Leticia Serra, Sudhir Thakurela, Vijay Tiwari, Dieter Weichenhan, Axel Benner, Bernhard Radlwimmer, Hanswalter Zentgraf, Stefan Wiemann, Karsten Rippe, Christoph Plass, Hartmut Döhner, Peter Lichter, Stephan Stilgenbauer & Daniel Mertens. (2013) Epigenetic Upregulation of lncRNAs at 13q14.3 in Leukemia Is Linked to the In Cis Downregulation of a Gene Cluster That Targets NF-kB. PLoS Genetics 9:4, pages e1003373.
Crossref
Crossref
Tadeusz Robak. (2013) Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. Future Oncology 9:1, pages 69-91.
Crossref
Crossref
Christine E. Gilling, Amit K. Mittal, Nagendra K. Chaturvedi, Javeed Iqbal, Patricia Aoun, Philip J. Bierman, Robert G. Bociek, Dennis D. Weisenburger & Shantaram S. Joshi. (2012) Lymph node-induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin-1. British Journal of Haematology 158:2, pages 216-231.
Crossref
Crossref
Che-Leung Law & Iqbal S. Grewal. 2009. Therapeutic Targets of the TNF Superfamily. Therapeutic Targets of the TNF Superfamily
8
36
.
Sharmila Bapat. 2008. Cancer Stem Cells. Cancer Stem Cells
27
55
.
B M Pickering, S de Mel, M Lee, M Howell, F Habens, C L Dallman, L A Neville, K N Potter, J Mann, D A Mann, P W M Johnson, F K Stevenson & G Packham. (2006) Pharmacological inhibitors of NF-κB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 26:8, pages 1166-1177.
Crossref
Crossref
Chongmin Huan, Matthew L Kelly, Ryan Steele, Iuliana Shapira, Susan R S Gottesman & Christopher A J Roman. (2006) Transcription factors TFE3 and TFEB are critical for CD40 ligand expression and thymus-dependent humoral immunity. Nature Immunology 7:10, pages 1082-1091.
Crossref
Crossref
Elaine J. Schattner, Richard R. Furman & Alejandro Bernal. 2006. NF-κB/Rel Transcription Factor Family. NF-κB/Rel Transcription Factor Family
131
146
.
Sofie Lust, Barbara Vanhoecke, Ann Janssens, Jan Philippe, Marc Bracke & Fritz Offner. (2005) Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. Molecular Nutrition & Food Research 49:9, pages 844-850.
Crossref
Crossref
Graham Packham & Freda K. Stevenson. (2005) Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology 114:4, pages 441-449.
Crossref
Crossref
M Farahani, A T Treweeke, C H Toh, K J Till, R J Harris, J C Cawley, M Zuzel & H Chen. (2005) Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia 19:4, pages 524-530.
Crossref
Crossref
Georgios V. Georgakis & Anas Younes. 2005. Cytokines and Cancer. Cytokines and Cancer
69
102
.
Dimitris Daoussis, Andrew P. Andonopoulos & Stamatis-Nick C. Liossis. (2004) Targeting CD40L: a Promising Therapeutic Approach. Clinical and Vaccine Immunology 11:4, pages 635-641.
Crossref
Crossref
M. von Bergwelt-Baildon, B. Maecker, J. Schultze & J.G. Gribben. (2004) CD40 activation: potential for specific immunotherapy in B-CLL. Annals of Oncology 15:6, pages 853-857.
Crossref
Crossref
Amit Panwalkar, Srdan Verstovsek & Francis Giles. (2004) Nuclear factor‐KappaB modulation as a therapeutic approach in hematologic malignancies. Cancer 100:8, pages 1578-1589.
Crossref
Crossref
Vonda K. Douglas & Raul C. Braylan. 2004. Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemia
145
161
.
Mira Grdisa. (2003) Influence of CD40 ligation on survival and apoptosis of B-CLL cells in vitro. Leukemia Research 27:10, pages 951-956.
Crossref
Crossref
Tommy Alain, Chandini Thirukkumaran, Donald G. Morris, Stefan J. Urbanski, Anna Janowska-Wieczorek, Patrick W.K. Lee & Anna E. Kossakowska. (2003) Lymphomas and Oncolytic Virus Therapy. Clinical Lymphoma 4:2, pages 104-111.
Crossref
Crossref
Chandini M. ThirukkumaranJoanne M. LuiderDouglas A. StewartTina ChengSasha M. LupichukMichael J. NodwellJames A. RussellIwona A. AuerDonald G. Morris. (2003) Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood 102:1, pages 377-387.
Crossref
Crossref
Hai Li, Xun Ma, Tibor Moskovits, Giorgio Inghirami & Vincent K Tsiagbe. (2003) Identification of oligoclonal CD4 T cells in diffuse large B cell lymphomas. Clinical Immunology 107:3, pages 160-169.
Crossref
Crossref
Tommy AlainKensuke HirasawaKelly J. PonSandra G. NishikawaStefan J. UrbanskiYvonna AuerJoanne LuiderAnita MartinRandal N. JohnstonAnna Janowska-WieczorekPatrick W. K. LeeAnna E. Kossakowska. (2002) Reovirus therapy of lymphoid malignancies. Blood 100:12, pages 4146-4153.
Crossref
Crossref
Liliana Guzman‐Rojas, Jennifer C. Sims‐Mourtada, Roberto Rangel & Hector Martinez‐Valdez. (2002) Life and death within germinal centres: a double‐edged sword. Immunology 107:2, pages 167-175.
Crossref
Crossref
Nicholas P Webber, John O Mascarenhas, Mary K Crow, James Bussel & Elaine J Schattner. (2001) Functional properties of lymphocytes in idiopathic thrombocytopenic purpura. Human Immunology 62:12, pages 1346-1355.
Crossref
Crossref
Alejandro BernalRaymond D. PastoreZahra AsgaryShannon A. KellerEthel CesarmanHsiou-Chi LiouElaine J. Schattner. (2001) Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 98:10, pages 3050-3057.
Crossref
Crossref
P Yotnda, H Onishi, HE Heslop, D Shayakhmetov, A Lieber, M Brenner & A Davis. (2001) Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Therapy 8:12, pages 930-937.
Crossref
Crossref
. (2000) Current Awareness. Hematological Oncology 18:4, pages 161-168.
Crossref
Crossref
Richard R. Furman, Zahra Asgary, John O. Mascarenhas, Hsiou-Chi Liou & Elaine J. Schattner. (2000) Modulation of NF-κB Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells. The Journal of Immunology 164:4, pages 2200-2206.
Crossref
Crossref